

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purposes only and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for securities of Guanze Medical Information Industry (Holding) Co., Ltd. or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of Guanze Medical Information Industry (Holding) Co., Ltd. in any jurisdiction in contravention of applicable laws or regulations. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

**FUNDE (HONG KONG) INVESTMENT
HOLDINGS CO., LIMITED**

富德(香港)投資控股有限公司
(Incorporated in Hong Kong with limited liability)

**GUANZE MEDICAL INFORMATION
INDUSTRY (HOLDING) CO., LTD.**

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2427)

JOINT ANNOUNCEMENT

**DESPATCH OF COMPOSITE DOCUMENT
RELATING TO MANDATORY UNCONDITIONAL CASH OFFER
BY ARISTO SECURITIES LIMITED
FOR AND ON BEHALF OF
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
TO ACQUIRE ALL THE ISSUED SHARES OF
GUANZE MEDICAL INFORMATION
INDUSTRY (HOLDING) CO., LTD.
(OTHER THAN THOSE ALREADY OWNED AND/OR
AGREED TO BE ACQUIRED BY
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED,
ITS ULTIMATE BENEFICIAL OWNERS AND
PARTIES ACTING IN CONCERT WITH ANY OF THEM)**

Financial adviser to the Offeror



Financial adviser to the Company



Independent Financial Adviser to the Independent Board Committee

 **軟庫中華 SBI China**

Reference is made to (i) the joint announcements dated 11 February 2026 and 20 February 2026 in relation to the Offer; (ii) the joint announcements dated 4 March 2026 and 10 April 2026 in relation to the delay in despatch of composite document in relation to the Offer; and (iii) the composite document dated 17 April 2026 in relation to the Offer (the “**Composite Document**”), jointly issued by FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (the “**Offeror**”) and Guanze Medical Information Industry (Holding) Co., Ltd. (the “**Company**”). Unless otherwise stated, capitalised terms used in this joint announcement shall have the same meanings as those defined in the Composite Document.

DESPATCH OF THE COMPOSITE DOCUMENT

The Composite Document setting out, among other things, (i) the terms and conditions of the Offer; (ii) the expected timetable in respect of the Offer; (iii) a letter from Aristo Securities; (iv) a letter from the Board; (v) a letter from the Independent Board Committee containing its recommendation to the Independent Shareholders in respect of the Offer; and (vi) a letter from the Independent Financial Adviser containing its advice to the Independent Board Committee in respect of the Offer, together with the Form of Acceptance, have been despatched to the Independent Shareholders on 17 April 2026 in accordance with the Takeovers Code.

The Composite Document and the accompanying Form of Acceptance are also available on the websites of the Stock Exchange and the Company.

EXPECTED TIMETABLE

The Offer will be open for acceptance on and from Friday, 17 April 2026 and the latest time and date for acceptance of the Offer is 4:00 p.m. on Friday, 8 May 2026 unless the Offeror revises or extends the Offer in accordance with the Takeovers Code. The announcement of the results of the Offer will be made by 7:00 p.m. on Friday, 8 May 2026.

The expected timetable set out below is indicative only and may be subject to changes. Further announcement(s) will be made in the event of any changes to the timetable as and when appropriate. Unless otherwise specified, all time and date references contained in this joint announcement refer to Hong Kong local time and dates.

Event	Time & Date 2026
Despatch date of the Composite Document and the accompanying Form of Acceptance ^(Note 1)	Friday, 17 April
Offer opens for acceptance ^(Note 1)	Friday, 17 April
Latest time and date for acceptance of the Offer ^(Notes 2, 3 and 5)	by 4:00 p.m. on Friday, 8 May
Closing Date ^(Notes 3 and 5)	Friday, 8 May
Announcement of the results of the Offer (or its extension or revision, if any) on the website of the Stock Exchange ^(Notes 3 and 5)	no later than 7:00 p.m. on Friday, 8 May
Latest date for posting of remittances in respect of valid acceptances received under the Offer ^(Notes 4 and 5)	Tuesday, 19 May

Notes:

1. The Offer, which is unconditional in all respects, is made on the date of posting of the Composite Document, and is capable of acceptance on and from that date until 4:00 p.m. on the Closing Date, unless the Offeror decides to revise or extend the Offer in accordance with the Takeovers Code. Acceptances of the Offer shall be irrevocable and not capable of being withdrawn, except in the circumstances set out in the paragraph headed “6. Right of Withdrawal” in Appendix I to the Composite Document.
2. Beneficial owners of Shares who hold their Shares in CCASS directly as an investor participant or indirectly via a broker or custodian participant should note the timing requirements (as set out in the paragraph headed “1. General Procedures for Acceptance of the Offer” in Appendix I to the Composite Document) for causing instructions to be made to CCASS in accordance with the General Rules of CCASS and CCASS Operational Procedures.
3. In accordance with the Takeovers Code, the Offer must initially be open for acceptance for at least 21 days after the date of the Composite Document. The latest time and date for acceptance of the Offer is 4:00 p.m. on Friday, 8 May 2026 unless the Offeror revises or extends the Offer in accordance with the Takeovers Code. An announcement will be issued jointly by the Offeror and the Company through the website of the Stock Exchange by 7:00 p.m. on the Closing Date stating whether the Offer has been extended, revised or expired. In the event that the Offeror decides to revise or extend the Offer, all Independent Shareholders, whether or not they have already accepted the Offer, will be entitled to accept the revised Offer under the revised terms. The revised Offer must be kept open for at least 14 days after the date of the revised offer document(s) and shall not close earlier than the Closing Date.

4. Remittances in respect of the cash consideration (after deducting the seller's ad valorem stamp duty) payable for the Offer Shares tendered under the Offer will be despatched to the Independent Shareholders accepting the Offer by ordinary post at their own risk as soon as possible, but in any event no later than seven (7) Business Days after the date of receipt by the Registrar of all relevant documents required to render such acceptance complete and valid in accordance with the Takeovers Code.
5. If there is a tropical cyclone warning signal number 8 or above, or a "black rainstorm warning signal" or "extreme conditions" as announced by the Hong Kong Government:
 - (a) in force in Hong Kong at any local time before 12:00 noon but no longer in force at or after 12:00 noon on the latest date for acceptance of the Offer under Rule 15.1 of the Takeovers Code, any publication date of a closing announcement under Rule 19.1 of the Takeovers Code or the latest date for posting of remittances for the amounts due under the Offer in respect of valid acceptances, these dates, as the case may be, will remain on the same Business Day; or
 - (b) in force in Hong Kong at any local time at 12:00 noon and/or thereafter on the latest date for acceptance of the Offer under Rule 15.1 of the Takeovers Code, any publication date of a closing announcement under Rule 19.1 of the Takeovers Code or the latest date for posting of remittances for the amounts due under the Offer in respect of valid acceptances, these dates, as the case may be, will be rescheduled to the following Business Day which does not have any of those warnings or condition in force in Hong Kong at any local time at 12:00 noon and/or thereafter or such other day as the Executive may approve in accordance with the Takeovers Code.

Save as mentioned above, if the latest time for acceptance of the Offer does not take effect on the date and time as stated above, the other dates subsequent to the latest time and date for acceptance of the Offer mentioned in the expected timetable above may be affected. The Offeror and the Company will notify the Independent Shareholders by way of joint announcement(s) on any change to the expected timetable as soon as practicable.

IMPORTANT

The Offer is unconditional in all respects. The Independent Shareholders are strongly advised to read the Composite Document and the Form of Acceptance carefully, including the recommendations from the Independent Board Committee to the Independent Shareholders and the advice from the Independent Financial Adviser to the Independent Board Committee, before deciding whether or not to accept the Offer.

The Independent Shareholders and/or potential investors of the Company should exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult a licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional advisers.

The Offeror and the Company remind their respective associates of the dealing restrictions under the Takeovers Code and to disclose their permitted dealings, if any, in any securities of the Company.

By order of the board
**FUNDE (HONG KONG) INVESTMENT
HOLDINGS CO., LIMITED**
Zhang, David Jia-yuan
Sole director

By order of the Board
**Guanze Medical Information
Industry (Holding) Co., Ltd.**
Meng Xianzhen
Chairman and executive Director

Hong Kong, 17 April 2026

As at the date of this joint announcement, Mr. Zhang is the sole director of the Offeror. As at the date of this joint announcement, Mr. Cheung is the sole director of Shenzhen City Junde Investment Co., Ltd. (深圳市峻德投資有限公司), the ultimate parent company of the Offeror.*

Each of the sole director of the Offeror (being Mr. Zhang) and the sole director of the ultimate parent company of the Offeror (being Mr. Cheung) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Group, the Selling Shareholder and its ultimate beneficial owner), and confirms, having made all reasonable enquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than those expressed by the Directors in their capacities as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Board comprises Mr. Meng Xianzhen (Chairman) and Mr. Guo Zhenyu as executive Directors, Ms. Meng Cathy as non-executive Director, and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them), and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by each of the sole director of the Offeror and the sole director of the ultimate parent company of the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

In the event of any inconsistency, the English text of this joint announcement shall prevail over its Chinese text.

* *For identification purpose only*